Grundstrm, H., Kjlhede, P., Berter, C., & Alehagen, S
Introduction The introduction of contemporary therapies for childhood T-cell acute lymphoblastic leukemia (T-ALL) has resulted in remission rates that are closer to that of B-cell precursor (BCP) ALL but survival rates remain lower and 15-20% of children with T-ALL die from relapsed/refractory disease.1 Patients with high-risk disease or those who relapse often receive more intensive treatment, making them more susceptible to toxicity and long-term secondary complications.2 This highlights the need to investigate other agents to treat this disease
The thymus, which is frequently enlarged in thyroiditis as it is in Graves' disease, does not present the picture of enhanced immunologic activity(13),(14)
No peptide directly mimics BMP but some enhance endogenous BMP production
Gene structure and spatiotemporal expression profile of tomato genes encoding YUCCA-like flavin monooxygenases: the ToFZY gene family
doi: 10.1016/j.bbamem.2015.11.005